Top

BY Ron Gilmore

Whether it is new clinical trials for pediatric cancers or programs designed to increase access to smoking cessation programs for low-income pregnant women, there are few areas related to cancer prevention, treatment or research untouched by the funding received by MD Anderson from the Cancer Prevention and Research Institute of Texas (CPRIT).

MD Anderson and its projects have been fortunate to have received $447.6 million, or...

Michael Andreeff, M.D., Ph.D., professor of Leukemia, in his laboratory

BY Clayton R. Boldt, Ph.D.

Neoadjuvant therapy is treatment, such as chemotherapy or radiation, given before a patient has surgery. This approach is used in many cancer...

BY Clayton R. Boldt, Ph.D.

MD Anderson’s proteomics platform provides a valuable institutional resource, complete with state-of-the-art instruments and specialized expertise...

BY Clayton R. Boldt, Ph.D.

Chronic lymphocytic leukemia (CLL), which originates in white blood cells known as lymphocytes, is the most common form of leukemia in adults. According to the American Cancer Society, more than 20,000 new cases of the leukemia will be diagnosed in the U.S. this year, and nearly 4,000 people will die from the disease.

Built upon the long-standing expertise of clinicians and researchers at MD Anderson, the CLL Moon Shot™ is working...

photo illustration CLL Moon Shot

BY Jill Russell, Ph.D.

Glioblastoma is the most common, aggressive and deadly form of brain cancer. Median overall survival for primary glioblastoma is 14.6 months...

BY MD Anderson staff

This is the second part of Cancer Frontline’s interview with Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology...

BY MD Anderson staff

In October 2018, the Nobel Prize in Physiology or Medicine was awarded to Jim Allison, Ph.D., chair of Immunology, for his discoveries on...

BY Clayton R. Boldt, Ph.D.

MD Anderson Cancer Center researchers, together with collaborators from Mozambique, Brazil and the U.S., have been awarded a $5.1 million...

BY Andrew Olin

A Dream Team assembled by Stand Up To Cancer will receive $8 million in funding to research the use of modified immune cells to fight...

BY Devon Carter

DNA damage response (DDR) inhibitors, such as poly (ADP-ribose) polymerase (PARP) inhibitors, are a type of targeted therapy used to treat...